Gamaleya claims the Sputnik V perfect booster against Omicron

Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response

WHO grants EUL for Covovax

First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine

2022: Predictions for medical and healthcare industry

2022 is going to be the year of opportunities and innovations from the medical industry in India

New data suggests Covaxin generates robust memory to Covid-19 and variants six months after vaccination

Effectiveness of Covaxin against the Omicron variant is currently being studied

Six benefits of Cloud Computing in the pharma industry

Moderna to set up mRNA vaccine manufacturing facility in Australia

Up to 100 million mRNA vaccine doses could be produced in Australia each year

Medicago and GSK’s plant based Covid-19 vaccine candidate show promise in Phase 3 trials

Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants

Three doses of Pfizer-BioNTech vaccine protects against Omicron: Study

According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron

RDIF offers vaccine for adolescents aged 12-17 in India

Sputnik M is a new member of the Sputnik vaccines family

Hilleman Laboratories invests US $ 58 mn to establish vaccine hub in Singapore

The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.